Company · CIK 0001521036 · SIC 2835 — In Vitro & In Vivo Diagnostic Substances · Nasdaq
Lantheus Holdings, Inc. · LNTH
Insider activity reported against this company. All insider holders · Files at: CATX. On EDGAR ↗
Reported at this company — common stock
| Trade | Reported (ET) | Insider | Shares | Avg price | Total | Owned after | Δ stake | Flags |
|---|---|---|---|---|---|---|---|---|
| Aug 31, 2026 FForm 4 → | Sep 2, 4:35 pm EDT | Robert J. Marshall Jr.CFO and Treasurer | 721 | $100.96 | $72,792 | 122,071 | — | |
| Aug 17, 2026 FForm 4 → | Aug 19, 4:34 pm EDT | Ludger DinkelborgSee Remarks | 2,536 | $100.91 | $255,908 | 33,195 | — | |
| Aug 17, 2026 FForm 4 → | Aug 19, 4:34 pm EDT | Kimberly BrownChief Accounting Officer | 463 | $100.91 | $46,721 | 13,263 | — | |
| May 14, 2026 FForm 4 → | Jun 3, 4:44 pm EDT | Gerard BerDirector | 381 | $96.67 | $36,831 | 27,118 | — | late |
| May 14, 2026 FForm 4 → | Jun 3, 4:43 pm EDT | Mary Anne HeinoExecutive Chair and CEO, Director | 1,227 | $96.67 | $118,614 | 321,897 | — | late |
Reported at this company — derivatives (options, RSUs, warrants)
No reported derivative activity in this period.
Filed by this entity as an insider elsewhere — common stock
| Trade | Reported (ET) | Company | Shares | Avg price | Total | Owned after | Δ stake | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 1, 2026 SForm 4 → | Sep 3, 4:54 pm EDT | Perspective Therapeutics, Inc.CATX | 35,769 | $3.12 | $111,574 | 11,563,425 | −0.31% | |
| Aug 31, 2026 SForm 4 → | Sep 2, 4:36 pm EDT | Perspective Therapeutics, Inc.CATX | 78,145 | $3.14 | $245,610 | 11,599,194 | −0.67% |
Filed by this entity as an insider elsewhere — derivatives (options, RSUs, warrants)
No reported derivative activity in this period.